SVCM
Saturn V Capital Management Portfolio holdings
AUM
$247M
This Quarter Return
-8.04%
1 Year Return
+2.68%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$255M
AUM Growth
+$255M
(-8.7%)
Cap. Flow
+$9.39M
Cap. Flow
% of AUM
3.68%
Top 10 Holdings %
Top 10 Hldgs %
71.55%
Holding
30
New
5
Increased
10
Reduced
8
Closed
6
Top Buys
| 1 |
Xenon Pharmaceuticals
XENE
|
$12.6M |
| 2 |
CTNM
Contineum Therapeutics
CTNM
|
$7.26M |
| 3 |
Syndax Pharmaceuticals
SNDX
|
$6.43M |
| 4 |
Merus
MRUS
|
$4.35M |
| 5 |
Amylyx Pharmaceuticals
AMLX
|
$3.36M |
Top Sells
| 1 |
Phathom Pharmaceuticals
PHAT
|
$15.8M |
| 2 |
Neumora Therapeutics
NMRA
|
$5.72M |
| 3 |
BioMarin Pharmaceuticals
BMRN
|
$2.63M |
| 4 |
Crinetics Pharmaceuticals
CRNX
|
$2.58M |
| 5 |
iTeos Therapeutics
ITOS
|
$2M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Disc Medicine
IRON
$2.07B
| $32.3M | 12.65% | 509,406 -1,635 | -0.3% | -$104K |
|
2
Ascendis Pharma
ASND
$11.8B
| $27.4M | 10.73% | 198,977 -1,308 | -0.7% | -$180K |
|
3
MoonLake Immunotherapeutics
MLTX
$3.54B
| $18.7M | 7.34% | 346,111 +47,137 | +16% | +$2.55M |
|
4
CG Oncology
CGON
$2.04B
| $17M | 6.66% | 593,262 +73,143 | +14% | +$2.1M |
|
5
Vaxcyte
PCVX
$4B
| $16.7M | 6.55% | 204,285 -702 | -0.3% | -$57.5K |
|
6
Cytokinetics
CYTK
$4.23B
| $16.4M | 6.42% | 348,364 +17,081 | +5% | +$803K |
|
|
CRGX
7
DELISTED
CARGO Therapeutics
CRGX
| $14.5M | 5.69% | 1,007,677 +5,216 | +0.5% | +$75.2K |
|
8
Celcuity
CELC
$2.17B
| $13.9M | 5.45% | 1,063,783 +117,448 | +12% | +$1.54M |
|
|
9
Syndax Pharmaceuticals
SNDX
$1.41B
| $13.1M | 5.12% | 988,528 +486,550 | +97% | +$6.43M |
|
|
10
Xenon Pharmaceuticals
XENE
$2.98B
| $12.6M | 4.95% | +322,470 | New | +$12.6M |
|
11
argenx
ARGX
$43.6B
| $12.1M | 4.76% | 19,754 -2,357 | -11% | -$1.45M |
|
12
Cogent Biosciences
COGT
$1.69B
| $11.7M | 4.58% | 1,498,425 -214,474 | -13% | -$1.67M |
|
|
13
Merus
MRUS
$4.98B
| $9.87M | 3.86% | 234,637 +103,397 | +79% | +$4.35M |
|
|
CTNM
14
Contineum Therapeutics
CTNM
$293M
| $8.39M | 3.29% | 573,022 +495,725 | +641% | +$7.26M |
|
|
ABVX
15
Abivax
ABVX
$6.12B
| $4.78M | 1.87% | 653,071 +5,052 | +0.8% | +$37K |
|
16
KalVista Pharmaceuticals
KALV
$678M
| $4.71M | 1.85% | 556,489 | – | – |
|
|
INZY
17
DELISTED
Inozyme Pharma
INZY
| $3.81M | 1.49% | 1,374,582 +5,772 | +0.4% | +$16K |
|
18
Ironwood Pharmaceuticals
IRWD
$214M
| $3.61M | 1.41% | 814,533 -305,876 | -27% | -$1.36M |
|
|
19
Amylyx Pharmaceuticals
AMLX
$836M
| $3.36M | 1.32% | +889,073 | New | +$3.36M |
|
|
20
Crinetics Pharmaceuticals
CRNX
$2.92B
| $3.02M | 1.18% | 59,125 -50,442 | -46% | -$2.58M |
|
|
SLN
21
Silence Therapeutics
SLN
$227M
| $2.72M | 1.06% | 395,024 -86,103 | -18% | -$592K |
|
22
NewAmsterdam Pharma
NAMS
$2.71B
| $2.57M | 1.01% | +100,000 | New | +$2.57M |
|
23
Ocular Therapeutix
OCUL
$2.12B
| $1.64M | 0.64% | +191,456 | New | +$1.64M |
|
|
MBX
24
MBX Biosciences, Inc. Common Stock
MBX
$507M
| $332K | 0.13% | +18,000 | New | +$332K |
|
|
25
BioMarin Pharmaceuticals
BMRN
$11.2B
| – | – | -37,432 | Closed | -$2.63M |
|